Investigational drug · Phase 2
SHR0302Base
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Vitiligo, Non-segmental Vitiligo.
Phase 2Last checked: Nov 19, 2026Latest source record: Feb 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
1
Any phase or sponsor naming "SHR0302Base"
First trial start
2025
Feb 13, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SHR0302Base", any sponsor or status.
Conditions studied
As listed on its trial records.
- Vitiligo
- Non-segmental Vitiligo
Approved drugs for the same conditions: Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "SHR0302Base" as an intervention, largest first.
- A Trial of SHR0302Base in Patients With VitiligoPivotal-lookingActive, not recruiting
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT06790862 · 155 participants · Start Feb 13, 2025 · Primary completion Mar 3, 2026
Drug: SHR0302Base gel; SHR0302Base gel placebo · For: Vitiligo
Sites: Jinan, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Vitiligo
- MH004Phase 32 trials
Minghui Pharmaceutical (Hangzhou) Ltd · Vitiligo, Atopic Dermatitis (AD)
- TEV-53408Phase 32 trials
Teva · Vitiligo, Celiac Disease
- GR2301Phase 22 trials
Genrix (Shanghai) Biopharmaceutical Co., Ltd. · Vitiligo
- LY4005130Phase 22 trials
Eli Lilly · Alopecia Areata, Vitiligo, Non-Segmental Vitiligo (NSV)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.